In this treatment setting, the anti-CSPG4-(PDD) administered in two 2 mg/kg doses significantly restricted tumor growth compared with isotype-(PDD) ADC, PDD payload alone, anti-CSPG4 plus unconjugated PDD or buffer control-treated groups. Here, CSPG4 is linked to neoplasm.